In this issue of Blood, Cieri et al and Roberto et al report that recovery of a diverse T-cell receptor (TCR) repertoire following haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using posttransplant cyclophosphamide (pt-Cy) is dependent on T memory stem cells (TSCM) maturing from naive T cells adoptively transferred in the donor graft.1,2 

These results considerably advance our understanding of how immune reconstitution occurs in the setting of haplo-HSCT. Historically, due to the increased risk of graft-versus-host disease (GVHD), outcomes for patients requiring allogeneic HSCT (allo-HSCT) have been inferior to results of sibling and matched unrelated donor HSCT. Fortunately, the past decade has seen dramatic advances in alternative donor transplantation, using either umbilical cord blood or haploidentical family donors. These developments are welcome, particularly for patients of minority groups, who are far less likely to find a registry match when lacking a sibling donor.3 

Because alloreactive T cells present in a native haploidentical donor graft would rapidly induce lethal GVHD in the recipient, the classic approach to haploidentical transplantation involved rigorously depleting donor T cells from the donor graft ex vivo, typically reducing transferred T cells by ∼1000-fold. The modern approach developed by Luznik, Fuchs, and colleagues was inspired by seminal studies, more than a half-century old, demonstrating induction of tolerance by the alkylating agent cyclophosphamide,4  and their own preclinical models of allogeneic transplantation.5  Subsequent human clinical trials demonstrated the feasibility of transplantation of an unmanipulated haploidentical graft if cyclophosphamide was administered to the recipient on days +3 and +4 following donor graft infusion.6 

The repercussions from these advances in haplo-HSCT have been widely felt. Following the original publication demonstrating the safety of pt-Cy administration, multiple publications from academic and even private settings have demonstrated the feasibility, safety, and efficacy of this approach in varied subgroups.7  In fact, recent data suggest an increase in haploidentical transplants performed with an attendant decrease in the utilization of cord blood transplantation, despite the lack of head-to-head clinical data demonstrating the superiority of this approach.8  Given its increasing use, significant attention is now being focused on the mechanisms of recipient T-cell recovery after pt-Cy, the subject of these 2 studies.

Gattinoni et al previously identified human early memory-stage T cells with stemlike properties (TSCM) that preferentially facilitated T-cell recovery in immunodeficient mice, similar to their multipotent murine counterparts.9  While expressing classical naive markers (eg, CD45RA, CD62L), human TSCM additionally expressed markers including the tumor necrosis factor receptor superfamily member and cellular death receptor Fas/CD95; in contrast to their true naive counterparts, this subpopulation proved low in the content of recent thymic emigrants and more readily produced cytokines upon polyclonal stimulation.

Recent preclinical and clinical studies have better defined the effects of pt-Cy on both alloreactive and nonalloreactive T-cell subsets. Kanakry et al recently demonstrated that the expression of aldehyde dehydrogenase, known to protect hematopoietic progenitors from the effects of cyclophosphamide, is also responsible for the relative preservation of regulatory T cells (Tregs) in murine and human subjects.10  In murine studies, Ganguly and colleagues further demonstrated that the adoptive transfer of donor Tregs is necessary for the protective effects of pt-Cy against GVHD.11  Additionally, our own murine studies have demonstrated that pt-Cy relatively spares pathogen and cancer-specific T cells expanding under lymphopenic conditions, whereas antigen engagement in the early post-HSCT era drives the preferential deletion of alloreactive T cells.12 

To add to this growing understanding of the effects of pt-Cy on immune recovery, the 2 new studies in this issue used parallel conceptual approaches, albeit in the setting of distinct haplo-HSCT subpopulations. Cieri et al studied patients receiving ablative conditioning and peripheral blood stem cell grafts, with recipients receiving, in addition to pt-Cy, mycophenolate mofetil (MMF) and sirolimus for GVHD prophylaxis.1  Roberto et al studied haploidentical recipients who received nonmyeloablative conditioning and marrow grafts, with GVHD prophylaxis consisting of pt-Cy, MMF, and calcineurin inhibition.2  Although the clinical approaches to haplo-HSCT differed, both investigative teams performed serial measurements of naive and TSCM T cells at early points following HSCT, including comprehensive immunophenotypic and functional measures, to assess patterns of immune reconstitution with a focus on early events following the administration of pt-Cy.

The novel and important finding of both studies is that in the early post-HSCT interval, the peripheral lymphoid pool was dominated by TSCM derived from naive donor graft T cells, and that TSCM were directly responsible for the recovery of a diverse TCR repertoire. Both studies used thorough immunophenotypic and functional analyses, which allowed indirect but meaningful conclusions to be drawn not only about TSCM, but also their precursor and derivative lymphoid subsets. The dramatic expansion of TSCM suggests a mechanism for the superiority of the pt-Cy approach to haplo-HSCT over the traditional approach of rigorous T-cell depletion. These studies highlight the importance of TSCM in immune recovery not only after haplo-HSCT, but also in the ontogeny of memory T-cell development more generally.

Although these studies are compelling, important questions remain. It remains possible that the expression of CD95 on naive T cells could be driven by activation events early after HSCT, when tissue injury, cytokine excess, and lymphopenia prevail, leading to a pseudo-TSCM phenotype (just as lymphopenia can push truly naive cells deprived of antigen in mice to masquerade as memory cells). Whereas these data suggest that TSCM are critical to memory rediversification in HSCT recipients, the present studies provide few concrete answers regarding how naive-to-TSCM transitions are directed, or how this maturation might be enhanced clinically. Such knowledge might even help us improve outcomes in cord blood transplantation in adults, which is characterized by delayed recovery of functional T-cell responses despite the transfer of uniformly naive T cells, in part due to delays in thymopoietic recovery.13  Although these and other questions remain, our maturing understanding of in vivo T-cell development inspires genuine hope that we will soon have active clinical strategies that may accelerate immune recovery in all allo-HSCT recipients, including those requiring alternative donors.

Conflict-of-interest disclosure: The author declares no competing financial interests.

1
Cieri
 
N
Oliveira
 
G
Greco
 
R
et al. 
Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation.
Blood
2015
, vol. 
125
 
18
(pg. 
2865
-
2874
)
2
Roberto
 
A
Castagna
 
L
Zanon
 
V
et al. 
Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.
Blood
2015
, vol. 
125
 
18
(pg. 
2855
-
2864
)
3
Gragert
 
L
Eapen
 
M
Williams
 
E
et al. 
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
N Engl J Med
2014
, vol. 
371
 
4
(pg. 
339
-
348
)
4
Berenbaum
 
MC
Brown
 
IN
Prolongation of homograft survival in mice with single doses of cyclophosphamide.
Nature
1963
, vol. 
200
 pg. 
84
 
5
Luznik
 
L
Jalla
 
S
Engstrom
 
LW
Iannone
 
R
Fuchs
 
EJ
Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
Blood
2001
, vol. 
98
 
12
(pg. 
3456
-
3464
)
6
Luznik
 
L
O’Donnell
 
PV
Symons
 
HJ
et al. 
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
Biol Blood Marrow Transplant
2008
, vol. 
14
 
6
(pg. 
641
-
650
)
7
Luznik
 
L
Bolaños-Meade
 
J
Zahurak
 
M
et al. 
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.
Blood
2010
, vol. 
115
 
16
(pg. 
3224
-
3230
)
8
Passweg
 
JR
Baldomero
 
H
Bader
 
P
et al. 
Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants [published online ahead of print February 2, 2015].
Bone Marrow Transplant
 
doi:10.1038/bmt.2014.312
9
Gattinoni
 
L
Lugli
 
E
Ji
 
Y
et al. 
A human memory T cell subset with stem cell-like properties.
Nat Med
2011
, vol. 
17
 
10
(pg. 
1290
-
1297
)
10
Kanakry
 
CG
Ganguly
 
S
Zahurak
 
M
et al. 
 
Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157
11
Ganguly
 
S
Ross
 
DB
Panoskaltsis-Mortari
 
A
et al. 
Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
Blood
2014
, vol. 
124
 
13
(pg. 
2131
-
2141
)
12
Ross
 
D
Jones
 
M
Komanduri
 
K
Levy
 
RB
Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation.
Biol Blood Marrow Transplant
2013
, vol. 
19
 
10
(pg. 
1430
-
1438
)
13
Komanduri
 
KV
St John
 
LS
de Lima
 
M
et al. 
Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.
Blood
2007
, vol. 
110
 
13
(pg. 
4543
-
4551
)
Sign in via your Institution